Baumann GP
Important Caveats About the Research Several important limitations should be acknowledged when reviewing the EpitalON literature: The majority of published studies originate from Khavinson's research group or closely affiliated laboratories Independent replication outside Russia has been limited, though the 2025 Biogerontology study represents a notable exception Human clinical data remains sparse, consisting mainly of small studies from one research group Most research has used injectable EpitalON, not oral formulations The peptide is not approved as a medicine in the UK, EU, or US How EpitalON Capsules Are Typically Taken Research Protocol Context The research literature commonly references cycles of 10-20 days at 5-10mg daily, repeated periodically (such as once or twice yearly)
Reduced, active form In your body, the reduced form of glutathione is better at scavenging for free radicals, fulfilling its role as an antioxidant
Pathologies of the haemolymphopoietic system Thrombocytopenia, leukopenia, anemia, agranulocytosis Immune system disorders Hypersensitivity reactions (urticaria, laryngeal edema, angioedema, anaphylactic shock) Nervous system disorders Dizziness Gastrointestinal disorders Gastrointestinal reaction Hepatobiliary pathologies Abnormal liver function, hepatitis Skin and subcutaneous tissue disorders Erythema multiforme, Stevens Johnson syndrome, Epidermal necrolysis, Skin rash Kidney and urinary disorders Acute renal failure, interstitial nephritis, hematuria, anuria
Date Y, Murakami N, Toshinai K, Matsukura S, Niijima A, Matsuo H, et al